Bydureon Infusion
Exenatide
2mg
BRISTOL-MYERS SQUIBB/ASTRAZENECA EEIG
| Pack size | 4 Single Dose Kit (2mg Powder Vial + 0.65ml Solvent PFS + Connector + Needles x 4) |
|---|---|
| Dispensing mode | POM |
| Source | UK |
| Agent | PHARMATRADE |
| Retail Price | 643.00 AED |
Indications
Bydureon Infusion is used for:
Indicated as adjunctive therapy to improve glycemic control in patients with Type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of both, but have not achieved adequate glycemic control.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Exenatide :
Mechanism of Action
Exenatide is a functional analog of the human incretin Glucagon-Like Peptide-1 (GLP-1). Incretins enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. The GLP-1 system increases insulin secretion only in the presence of elevated plasma glucose levels, avoiding inappropriately high insulin levels during fasting. The drug also moderates peak serum glucagon levels during hyperglycemic periods following meals, but does not interfere with glucagon release in response to hypoglycemia. Secondary effects of drug administration reduces the rate of gastric emptying and decreases food intake, mitigating the potential severity of hyperglycemic events after meals.
Note
Bydureon 2mg Infusion manufactured by BRISTOL-MYERS SQUIBB/ASTRAZENECA EEIG. Its generic name is Exenatide. Bydureon is availble in United Arab Emirates.
Farmaco UAE drug index information on Bydureon Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.